Pipeline
Indication Programs Preclinical IND Approval Phase 1 Phase 2 Phase 3 Brii Rights Partners
Infectious Disease Programs
HBV BRII-179 (VBI-2601)

Greater China

BRII-835 (VIR-2218)

Greater China

VIR-3434*
Greater China
HIV BRII-778
Global

BRII-732
Global

VIR-1111*

Greater China

MDR/XDR Gram
[-] Infections
BRII-636 (QPX-7728)*

Greater China

BRII-672 (QPX-7831)*

Greater China

BRII-693 (QPX-9003)

Greater China

MDR TB
Mycobacteria
BRII-658*

Greater China

COVID-19

BRII-196
Global
BRII-198
Global
Central Nervous System Disease Programs
PPD BRII-296
Global

MDD BRII-296
Global

* Indicates the status of the study being conducted by our partners
up
×
×
BRII-835(VIR-2218)
siRNA
Stage: Phase 2 
A novel, investigational RNA interference (RNAi) therapeutic designed to inhibit expression of all HBV proteins, including hepatitis B surface antigen (HBsAg). Viral protein knockdown may help restore the patient’s own immune response to HBV, thereby offering people living with chronic HBV the potential for a functional cure.
×
BRII-179(VBI-2601)
Recombinant Protein-based Immuno-therapeutics
Stage: Phase 2
Uniquely formulated to target both B-cell and T-cell immunity, we believe BRII-179 has the potential to induce HBV-specific adaptive immune responses and have the best chance to achieve sustained immune control leading to functional cure.
×
BRII-658
MDR/XDR TB antibiotic
Stage: Phase 1
A novel antibiotic for MDR and XDR tuberculosis (TB). We have the exclusive rights to develop and commercialize BRII-658 in Greater China.
×
BRII-636 (QPX-7728)
Beta-lactamase inhibitor
Stage: Phase 1
An intravenously administered, beta-lactamase inhibitor (BLI) in combination with an FDA-approved IV β-lactam antibiotic, targeting all WHO-designated critical pathogens of extensively drug resistant Acinetobacter, Enterobacteriaceae, and Pseudomonas in hospitalized patients. We have exclusive rights to develop and commercialize in Greater China.
×
BRII-672 (QPX-7831)
Beta-lactamase inhibitor
Stage: IND Approval
An orally administered BLI in combination with an FDA-approved oral β-lactam antibiotic, for the treatment of multi-drug resistant Gram-negative bacterial infections targeting extended spectrum beta-lactamase (ESBL) and/or carbapenemase producing Enterobacteriaceae as well as an oral step-down therapy to BRII-636. We have exclusive rights to develop and commercialize BRII-672 in Greater China.
×
BRII-693 (QPX-9003)
Next-generation Polymyxin
Stage: Preclinical
An IV-administered, targeted spectrum synthetic polymyxin with an enhanced therapeutic profile designed to address extensively drug resistant infections caused by Pseudomonas and Acinetobacter. We have exclusive rights to develop and commercialize in Greater China.
×
Novel treatment of HIV infections
Brii Bio has a very strong and proven track-record of delivering novel therapies to patients around the globe who are living with HIV. Current standard of care treatments has not addressed substantial patients’ need.
×
BRII-732
NRTI/NRTTI
Stage: IND Approval
Function as both a nucleoside reverse transcriptase inhibitor (NRTI) and a potent HIV reverse transcriptase translocation inhibitor (NRTTI). Together, the BRII-778/BRII-732 regimen offers all three distinct mechanisms of action: NRTI, NRTTI and NNRTI in one tablet. We are developing our BRII-778 and BRII-732 combination therapy as a once-weekly single tablet regimen.
×
BRII-778
NNRTI
Stage: Phase 1
An extended release non-nucleoside reverse transcriptase inhibitor (NNRTI). Together, the BRII-778/BRII-732 regimen offers all three distinct mechanisms of action: NRTI, NRTTI and NNRTI in one tablet. We are developing our BRII-778 and BRII-732 combination therapy as a once-weekly single tablet regimen.
×
BRII-196
Human monoclonal antibody
Stage: Phase 2
Isolated from a patient who has recovered from COVID-19, BRII-196 can completely block viral entry and neutralize live SARS CoV-2 infection in cell culture assays. It binds to a highly conserved epitope on the Spike protein and has the potential of becoming an effective therapy against the COVID-19 pandemic.
×
BRII-198
Human monoclonal antibody
Stage: Phase 2
Isolated from a patient who has recovered from COVID-19, it potently neutralizes live SARS CoV-2 infection. BRII-198 binds to a different epitope on the Spike protein and has additive to synergistic effect when combined with BRII-196. It has the potential of becoming an effective therapy against the COVID-19 pandemic.
×
Neurologic and Psychiatric Programs
We are advancing a preclinical pipeline focused on CNS diseases where we see vast opportunities to improve patient care by accelerating the development and delivery of breakthrough medicines and to open doors for our partners. We currently have multiple compounds in preclinical development.
×
BRII-296
Stage: Phase 1
A synthetic version of naturally occurring neuroactive steroid administered in a single intramuscular (IM) injection.
×
BRII-296
Stage: Preclinical
A synthetic version of naturally occurring neuroactive steroid administered in a single intramuscular (IM) injection.
×
Undisclosed
Stage: Discovery
We are advancing a preclinical pipeline focused on CNS diseases where we see vast opportunities to improve patient care by accelerating the development and delivery of breakthrough medicines and to open doors for our partners.
×
VIR3434
Monoclonal antibody
Stage: Phase 1
A monoclonal antibody targeting HBV that is currently in Phase 1 development by our partner Vir. We have an option to obtain exclusive rights to develop and commercialize in Greater China compounds and products arising from up to three additional programs in Vir’s pipeline that achieve clinical proof of concept. We will continue to monitor the clinical development progress of VIR-3434.
×
VIR1111
HIV Vaccine

Stage: Phase 1
An HIV T cell vaccine based on human cytomegalovirus (HVMC) designed to elicit T cells that recognize HIV epitopes and to stimulate a different and specific type of immune response to HIV known as HLA-E restricted immune response. We have an option to obtain exclusive rights to develop and commercialize in Greater China compounds and products arising from up to three additional programs in Vir’s pipeline that achieve clinical proof of concept. We will continue to monitor the clinical development progress of VIR-1111.